key: cord-0717165-h9uis2dm
authors: Medzikovic, Lejla; Cunningham, Christine M.; Li, Min; Amjedi, Marjan; Hong, Jason; Ruffenach, Gregoire; Eghbali, Mansoureh
title: Sex differences underlying preexisting cardiovascular disease and cardiovascular injury in COVID-19
date: 2020-08-22
journal: J Mol Cell Cardiol
DOI: 10.1016/j.yjmcc.2020.08.007
sha: 6a4547c4792c9cbe7b0fb7fd849c0edc1550514c
doc_id: 717165
cord_uid: h9uis2dm

The novel 2019 coronavirus disease (COVID-19), resulting from severe acute respiratory syndrome coronarvirus-2 (SARS-CoV-2) infection, typically leads to respiratory failure in severe cases; however, cardiovascular injury is reported to contribute to a substantial proportion of COVID-19 deaths. Preexisting cardiovascular disease (CVD) is among the most common risk factors for hospitalization and death in COVID-19 patients, and the pathogenic mechanisms of COVID-19 disease progression itself may promote the development of cardiovascular injury, increasing risk of in-hospital death. Sex differences in COVID-19 are becoming more apparent as mounting data indicate that males seem to be disproportionately at risk of severe COVID-19 outcome due to preexisting CVD and COVID-19-related cardiovascular injury. In this review, we will provide a basic science perspective on current clinical observations in this rapidly evolving field and discuss the interplay sex differences, preexisting CVD and COVID-19-related cardiac injury.

The novel 2019 coronavirus disease (COVID- 19) results from severe acute respiratory syndrome coronarvirus-2 (SARS-CoV-2) infection and typically afflicts the lungs, with severe cases leading to acute respiratory distress syndrome [1] . Although the respiratory system is the major organ system affected by SARS-CoV-2, cardiovascular complications should not be overlooked by healthcare workers and basic scientists. In particular, acute myocardial injury, cardiac arrhythmias and microvascular dysfunction and thrombosis are reported to contribute to a large proportion of COVID-19 deaths [2] [3] [4] [5] [6] [7] .

Patients with pre-existing cardiovascular disease (CVD) do not appear to be more prone to SARS-CoV-2 infection since the prevalence of CVD in COVID-19 cases is consistent with the high prevalence in the general population [5, 6, 8, 9] . However, pre-existing CVD is among the most common risk factors associated with hospitalizations, elevated cardiac injury biomarkers and death of COVID-19 patients [4, 10, 11] . As such, it is plausible that pre-existing CVD may exacerbate the course of disease and mortality in COVID-19 patients by promoting cardiovascular injury including myocardial damage, arrhythmias and microvascular dysfunction and thrombosis. Additionally, the pathogenic mechanisms of COVID-19 disease progression itself may be associated with the development of cardiovascular injury, which increases the risk of in-hospital death [12, 13] .

While there is a robust body of evidence elucidating sex differences in CVD, sex disparities in COVID-19 are becoming more apparent as well [14] . Interestingly, mounting data also indicate that individuals with higher risk of severe COVID-19 outcome due to preexisting CVD and COVID-19-related cardiovascular injury include a disproportionate number of males. In this review, we will discuss sex differences in the interplay between preexisting CVD, COVID-19 severity, and COVID-19-related cardiac injury by providing a basic science perspective based on the current literature in this rapidly evolving field.

As the clinical data surrounding COVID-19 infection and mortality rates continues to become more robust, a staggering trend is becoming apparent: COVID-19 positive males suffer worse disease progression and have a higher rate of mortality than females despite having a similar rate of infection [15] . The first published study investigating sex differences in the COVID-19 cases in China reports that men are more likely to experience serious illness and are 2.4 times more likely to die from COVID-19 while the average age of mortality and rate of infection remains the same for both sexes [15, 16] .

Sex differences in COVID-19 result from a complicated interplay between biological and societal influences, including preexisting CVD. Hypertension and history of CVD, both already known to increase COVID-19 severity and mortality [17] , display strong sex differences with males exhibiting a higher prevalence of disease compared to age-matched women, prior to menopausal years [18, 19] . On the other hand, women experience relatively worse outcomes of ischemic heart disease compared with men [20] . In HF, the overall lifetime risk is similar between men and women, there are marked sex differences in the variations of this condition, with males being predisposed to HF with reduced ejection fraction (HFrEF) and females to HF with preserved ejection fraction (HFpEF) [21] . In cardiac arrhythmias, the age-adjusted incidence of atrial fibrillation and Brugada syndrome is lower in women compared with that in men, whereas atrioventricular reentry tachycardia and cardiac events in long QT syndrome are more prevalent in adult females compared to males [22] . Lastly, male sex is an independent risk factor for various thrombotic events such as myocardial infarction, venous thromboembolism and thrombotic stroke [23] . In this section, we highlight sex differences in preexisting CVD and how they may contribute to the striking sex differences found in COVID-19 mortality.

Males exhibit increased risk of CVD compared to age-matched women, prior to menopausal years [18, 19] . These data indicate that individuals more at risk of severe COVID-19 outcome due to preexisting CVD include a disproportionate number of males.

The increased prevalence of CVD in males is multifactorial and well-studied with biological variables including sex hormones and their receptors as well as sex chromosomes. As detailed in a previous review from our group, the protective effects of estrogen have been well documented over the past few decades and may help explain why females of premenopausal age have lower incidence of CVD when compared to males [24, 25] . Exerting its effects through both genomic and non-genomic pathways, estrogen has been shown to ward off CVD through its effects on vasculature, cardiomyocytes and cardiac fibroblasts to promote vasodilation, angiogenesis, and cardiomyocyte survival while reducing cardiac fibrosis and oxidative stress [24] . More recently, the role of sex chromosomes has been implicated in the sex differences found in CVD as well [26] . Sex chromosomes, which differ between males (XY) and females (XX), can impart sex differences in disease through altered expression of genes encoded by the X and Y chromosomes [27] . Strikingly, studies that examined the effects of sex chromosome complement (XX or XY) in the absence of sex hormones reveal that XX chromosome complement increases the risk of developing CV complications including hypertension, atherosclerosis and ischemic injury [26, [28] [29] [30] . A handful of genes encoded by the X chromosome that escape inactivation on the second X chromosome in females are implicated as females have elevated expression of these genes compared to male, many of which are epigenetic modifiers. Taken together, premenopausal females seem to be protected against CVD when compared to males; however, with reduced levels of estrogen, post-menopausal women have an elevated risk of CVD complications. This increased risk could potentially prime older females with COVID-19 for more severe cardiac outcome, although more data is needed to parse apart the influence of menopause on COVID-19-related CVD complications.

Angiotensin-converting enzyme 2 (ACE2) is the functional receptor for SARS coronaviruses including the novel SARS-CoV-2 that causes COVID-19 [31, 32] . ACE-2, a carboxypeptidase transmembrane protein expressed in various cell types, regulates the activity of the renin-angiotensin system (RAS) by hydrolyzing angiotensin I (AngI) into Ang 1-9 and angiotensin II (AngII) into Ang 1-7 [33] . While ACE2 is homologous to ACE, the enzyme that converts AngI to the vasoconstrictive, pro-inflammatory, prohypertrophic and pro-fibrotic AngII, ACE2 counterbalances the detrimental effects of ACE [34] . ACE2 confers cardioprotection by enhancing vasodilation and preventing cardiac hypertrophy, fibrosis and oxidative stress. [34] ACE2-deficient mice exhibit elevated AngII levels, increased cardiac hypertrophy and fibrosis, and severe diastolic and systolic dysfunction, which is rescued by recombinant human ACE2 therapy [35, 36] .

While animal models and analysis of human hearts at the whole tissue level do not provide conclusive results regarding the directionality of cardiac ACE2 expression in CVD [37] [38] [39] [40] , CVD does augment ACE2 expression in cardiomyocytes. ACE2 expression is increased in cardiomyocytes of patients suffering from dilated and hypertrophic cardiomyopathy, aortic stenosis and HFrEF compared to control donor hearts [37, 41, 42] . Interestingly, cardiac pericytes, fibroblasts and vascular smooth muscle cells from these patients exhibited lower ACE2 expression compared to control donor hearts [37, 41] . Altered cardiac ACE2 expression profiles in CVD have been proposed as a mechanism underlying the more severe course of disease in COVID-19 patients with pre-existing CVD, since elevated cardiac ACE2 could mediate SARS-CoV-2 infection.

ACE2 is encoded by the X chromosome and is located in a region of the X chromosome that escapes Xinactivation in females [43] . Since females have two copies of the X chromosome compared to one copy in males, most X-escapee genes are found to have higher expression in females [44, 45] . ACE2, however, displays an uncharacteristically heterogeneous pattern across various tissues exhibiting increased mRNA expression in certain male tissues [44] . It is hypothesized that gene-hormone interactions accounts for this uncharacteristic pattern of expression as ACE2 activity has been demonstrated to be sex hormone dependent [46, 47] .

In the left ventricle (LV), hypertensive male rats (both spontaneously hypertensive and mRen2 strains) experience higher levels of ACE2 activity and hypertrophy when compared to females. [48, 49] Gonadectomy in males resulted in decreased ACE2 expression and reduced cardiac hypertrophy, whereas ovariectomy in females resulted in increased LV ACE2 activity and cardiac hypertrophy coupled with reduced hemodynamic function of the heart [49] . In contrast, studies using normotensive Lewis rats and MF1 mice did not demonstrate sexually dimorphic cardiac ACE2 activity [48, 50] . These studies, however, demonstrated that estrogen altered the expression and activity of ACE2 in other tissues including plasma, adipose tissue, and kidneys, while the effect of estrogen was varied. A study investigating the role of sex chromosomes in ACE2 activity revealed that while estrogen influenced ACE2 activity in the kidney of MF1 mice, sex chromosomes complement (XX or XY) had no effect [50] .

While ACE2 is encoded by the X chromosome, more highly expressed in certain male tissues than female tissues, and is influenced by estrogen, it is still unclear whether sexual dimorphisms in ACE2 directly contribute to the sex differences seen in COVID-19 severity and mortality. Even so, testing the use of short-term exogenous estrogen treatment as a therapy for COVID-19 patients is now underway in a Phase II clinical trial that includes both sexes (ID: NCT04359329) [51] .

Since AngII plays a central role in CVD pathophysiology, drugs that inhibit the activity of ACE (ACEi) or block AngII receptors (ARBs) are commonly prescribed as a first-line treatment. Sex differences exist in the cardiovascular efficacy and outcome of ARB and ACEi use, indicating differences in drug absorption, distribution, metabolism, and excretion between males and females [52] [53] [54] . Various ACEi and ARB have been shown to enhance expression and activity of cardiac ACE2 in experimental animal models. [55, 56] More recently, single-cell RNA sequencing (scRNAseq) revealed that hypertrophic cardiomyopathy patients taking ACEi trended towards elevated ACE2 expression in cardiomyocytes, fibroblasts, pericytes, and vascular smooth muscle cells [37] . Similarly, cardiomyocytes from ACEi-treated aortic stenosis and HFrEF patients exhibited enhanced ACE2 levels and unfavorable ACE/ACE2 ratios [41] . Since ACE2 is the main receptor of SARS-CoV-2, these studies led to initial concerns of enhanced susceptibility of SARS-CoV-2 infection; however, there is currently no proof that this outweighs their protective role in modulating RAS activity [41, 57] . In two recent studies, including a large observational study of 8910 COVID-19 patients, no association was found between the use of ACEi and ARB and increased likelihood of a positive SARS-CoV-2 test nor with increased risk of COVID-19 complications when corrected for sex, amongst others [58] . As such, effects of sex-specific efficacy of ARB and ACEi on COVID-19 progression and outcome seem unlikely.

Obesity is a major risk factor for developing CVD and emerging evidence shows that obesity is also risk factor of developing severe COVID-19 outcome and mortality. [59] [60] [61] [62] [63] [64] Sex differences in obesity are well established [65] . Obesity prevalence is significantly associated with sex and pathophysiological mechanisms of obesity are modulated by both sex hormones and chromosomes [65, 66] . Whether sex differences exist in the prevalence of obesity in COVID-19 patients is thus far not fully elucidated, but allude to higher prevalence of obese male COVID-19 patients than female. A study of 200 COVID-19 patients in New York City found no difference in proportion of males and females when COVID-19 patients were stratified by BMI [60] . However, studies of 383 Chinese and 92 Italian COVID-19 patients reported that the proportion of men was significantly higher in the overweight and obese BMI groups [61, 63] .

Interestingly, it is hypothesized that RAS dysregulation may link obesity to COVID-19 [67] . In line with this notion, an experimental mouse study reported that sex hormones contribute to tissue-specific ACE2 expression in the development of obesity-induced hypertension [47] . Here, high-fat diet fed females did not develop obesity-hypertension or elevated Ang 1-7 levels while males did. This effect was abolished upon ovariectomy and estrogen increased ACE2 levels. Considering the central role ACE2 and dysregulated RAS are thought to play in COVID-19, ACE2 may link sex differences, obesity, CVD and COVID-19.

In addition to biological factors, societal factors, including smoking, may also contribute to the sex differences present in COVID-19 [68] . Reports from 2015 reveal 52.1% of Chinese males smoke compared to just 2.7% of females [69] . Sex differences in smoking prevalence also exist in other populations, although to a much lesser degree (Italy: 26% Males, 17.2% Females [70] ; United States: 17.5% Males: 13.5% Females [71] ). According to a meta-analysis, history of smoking is one of the most prevalent preexisting factors associated with patients hospitalized for COVID-19 infection [17] . Studies show smoking is also a risk factor for the development of chronic obstructive pulmonary disease, hypertension, and CVD [72] , which are comorbidities positively associated with COVID-19 hospitalizations [17] . Single-cell RNAseq studies recently revealed an upregulation of the SARS-CoV-2 receptor, ACE2, in the lungs of smokers compared to never-smokers, which could influence the risk and severity of COVID-19 in smokers [73] . Taken together, the sex differences found among the smoking population may contribute to the sex differences in COVID-19 hospitalizations and morbidity. Smoking, which is largely more common in male populations, is associated with COVID hospitalization, can lead to cardio-pulmonary comorbidities, and upregulates the expression of ACE2 within the lung.

Cardiovascular injury in COVID-19 is mainly observed in the form of acute cardiac injury, microvascular injury and thrombosis. Various pathophysiological mechanisms may contribute to the development COVID-19-related cardiovascular injury including direct cardiotropic and endothelial viral infection, secondary systemic toxicity of the hyperinflammatory state, cardiovascular stress due to SARS-CoV-2induced respiratory failure, or a combination of all three factors [74, 75] . Sex disparities underlie some of these factors leading to COVID-19-related cardiovascular injury.

J o u r n a l P r e -p r o o f

Cardiac involvement is a prominent feature in COVID-19 pathophysiology. Acute myocardial damage in COVID-19 patients may be inferred from elevated circulating biomarkers, electrocardiographic changes, and imaging studies revealing features of impaired cardiac function [76] . Acute cardiac injury, based on circulating biomarkers, is more frequent in severe compared to non-severe COVID-19 cases [10, 77, 78] and circulating biomarker concentration is associated with disease severity and fatality [10, [78] [79] [80] . Altogether, up to 36% of COVID-19 patients were reported to suffer from acute cardiac injury based on elevated cardiac biomarkers [6, 10, 77, 80] .

While data is still emerging, some sex disparities seem to exist in COVID-19-related cardiac injury. A study of 112 Chinese COVID-19 patients has shown a trend towards more men being diagnosed with possible myocarditis than women [11] . Similarly, two studies of Chinese COVID-19 patients showed that women account for more of the mild cases which also exhibited lower levels of troponin I, creatine kinase-myocardial band fraction, myoglobin, and N-terminal B-type brain natriuretic peptide [79, 81] . In a study of 1557 COVID-19-positive individuals in New Haven, more males presented with abnormally elevated troponin T [16] . A larger study of 2736 COVID-19 patients in New York City, however, reported no significant sex differences when COVID-19 patients were stratified by troponin T levels [80] . In a study of 1557 COVID-19-positive individuals in New Haven, more males presented with abnormally elevated troponin T than females [16] . Interestingly, in this patient population, a model of combined risk factors including, age, hypertension and body mass index, showed that prostatic disease increased the odds of COVID-19 patients having elevated troponin T levels, independently of the other risk factors [16] . Together these data indicate that individuals more at risk of severe COVID-19 progression and outcome due to cardiac injury may include a disproportionate number of males.

The clinical burden of cardiac arrhythmias in COVID-19 patients is becoming increasingly clear. Various forms of cardiac atrial and ventricular rhythm disorders have been reported in COVID-19 patients including atrial fibrillation, sinus tachycardia and bradycardia, complete conduction block and cardiac arrest [82] . Arrhythmia may associate with sudden cardiac death, which is a pathologic outcome also observed in COVID-19 patients [83] [84] [85] . Arrhythmia in COVID-19 patients is associated with myocardial injury and is thought to reflect the severity of illness [81, 86, 87] . Indeed, ICU admission is associated with arrhythmia, with up to 44% of COVID-19 patients in the ICU suffering from arrhythmia [5, 88] . While the association of arrhythmias and in-hospital mortality in COVID-19 patients is inconclusive, it has been reported that the prevalence of arrhythmia is 60% in fatal COVID-19 cases [89] .

Sex differences exist in cardiac electrophysiological characteristics as female sex is a known risk factor for drug-induced QT prolongation and torsade des pointes arrhythmia [90] . Whether sex differences exist in arrhythmia in COVID-19 patients remains under-reported. Since arrhythmia is associated with myocardial damage and elevated cardiac biomarkers are more prevalent in male COVID-19 patients, it is plausible that arrhythmia may also be more prevalent in male COVID-19 patients. However, a Chinese study of 234 COVID-19 patients shows no differences between the proportion of male and female COVID-19 patients with or without arrhythmia [86] . Future studies will be imperative to shed light on sex disparities in arrhythmia occurrence in COVID-19 patients. elevated clot formation and fibrinolysis. [91] Elevated D-dimers were found to be associated with poor prognosis and increased risk of death. [4, 92] Histology on post-mortem lungs and skin from COVID-19 patients revealed thrombogenic vasculopathy [93, 94] . Moreover, thromboembolisms have been observed in several organs in COVID-19 patients [95] [96] [97] . Overall, 20-30% of COVID-19 patients in the ICU have been reported to suffer from thrombosis and major thromboembolic sequelae [7] .

While data on sex differences in microvascular injury and thrombosis in COVID-19 is still sparse, sex disparities do not seem to be observed. A study of 248 Chinese COVID-19 patients shows that there is no significant difference in proportion of male and females in normal and high D-dimer groups. [98] Accordingly, a meta-analysis reported that elevated D-dimer in severe COVID-19 cases and non-survivors do not seem to associate with sex [99] . Interestingly however, an Italian study of 100 COVID-19 patients reported that fibrinogen levels in female COVID-19 patients were significantly higher compared to female controls, while this increase was not significant in males [100] .

Cardiac samples from patients who succumbed to the previous SARS coronavirus in 2003 provides insight into the cardiotropic potential of coronaviruses. SARS-CoV, which also binds to the ACE2 receptor, was detected in 35% of hearts [101] and present in cardiomyocytes that displayed vacuolar degeneration, atrophy and cytoplasmic lysis [102] . While SARS-CoV-2 has been detected in hearts of COVID-19 patients, no reports yet have shown conclusive evidence of direct SARS-CoV-2 infection in non-inflammatory myocardial cells in COVID-19 patients [103] [104] [105] [106] . Several cell cardiac cell types express ACE2, including cardiomyocytes [107] . Recently, it was demonstrated that SARS-CoV-2 was able to infect human inducible pluripotent stem cell-derived cardiomyocytes in vitro, suggesting the potential for SARS-CoV-2 cardiotropic potential [108] .

While data on sex differences in cardiotropic SARS-CoV-2 is yet unavailable, sex disparities do exist in the epidemiology and pathophysiology of viral myocarditis induced by various viruses, and this may also be the case for SARS-CoV-2 [109] [110] [111] . Expression of the SARS-CoV-2 receptor ACE2 is regulated by sex hormones in opposite directions in male and female mice [49] . A recent study reported that androgen signaling may regulate ACE2 expression and subsequent SARS-CoV-2 infection in human cardiac cells since treatment with the 5 alpha reductase inhibitor dutasteride and androgen receptor modulator spironolactone augmented ACE2 levels and internalization of SARS-CoV-2 recombinant spike receptor binding domain in human embryonic stem cell-derived cardiac cells [16] . As such, sex hormones may underlie possible sex differences in cardiotropic SARS-CoV-2 infection by regulating ACE2 expression.

Microvascular injury and thrombosis in COVID-19 are thought to be caused by endothelial dysfunction since activated and injured endothelial cells recruit inflammatory cells and activate the coagulation cascade [112] . Histology on post-mortem from COVID-19 patients revealed that SARS-CoV-2 is able to directly infect endothelial cells concomitant with endothelialitis and apoptosis in several organs [113] . Accordingly, SARS-CoV-2 was shown to be able to directly infect human blood vessel organoids in vitro [114] .

Sex differences in endothelial dysfunction are well-established [115] . For instance, estrogen promotes proper endothelial cell function by enhancing endothelial nitric oxide synthase (eNOS) expression while testosterone has opposite effects [24] . A hallmark of endothelial dysfunction is dampened eNOS expression with NO deficiency [116] . Decreased NO levels in injured endothelial cells contribute to thrombus formation [112] . Recently it was proposed that eNOS deficiency could be a pathophysiological mechanism in COVID-19 [116] . As such, sex hormones may affect endothelial dysfunction in COVID-19. However, also in the absence of sex hormones, sex differences exist in barrier integrity and survival between male XY and female XX microvascular endothelial cells [117, 118] . Although sex-differences in COVID-19-related microvascular injury and thrombosis in the clinic do not seem apparent thus far, it is plausible that sex-differences play a pathophysiological role in COVID-19 endothelial dysfunction.

Upon binding to ACE2 on the cell surface, SARS-CoV-2 is endocytosed leading to downregulated ACE2 cell surface expression [119] . As such, the protective effects of ACE2 are likely blunted. Loss of membrane-bound ACE2 is hypothesized to be a critical step in the cardiac injury pathology in COVID-19. This notion is supported by experimental animal models wherein ACE2-deficient mice exhibit hypertrophy, fibrosis, HF and enhanced inflammation [35, 36, 120] . Autopsy material from the SARS epidemic revealed SARS-CoV infection in 35% of cardiac specimens concomitant with decreased membrane ACE2 levels, cardiac hypertrophy, inflammation, and fibrosis [120] , indicating that loss of membrane-bound ACE2 indeed may be a pathogenic mechanism in SARS-CoV-induced cardiac injury. Similarly, ACE2 expression and activation in endothelial protects against endothelial dysfunction in atherosclerosis, hypertension and thrombosis [121] [122] [123] . It has been shown that ACE2 is released into the circulation which advances several CVD pathologies, and levels of soluble ACE2 in plasma correlate with worsened disease severity and prognosis in HF patients [34, 124] . To date, no reports are available on levels of cardiac membrane-bound ACE2 or circulating levels of soluble ACE2 in COVID-19 patients. However, it seems that men, who are at increased risk of more severe COVID-19 progression, present with higher soluble ACE2 levels than women as was observed in both healthy subjects and two independent cohorts of HF patients [125, 126] .

SARS-CoV-2 infection is characterized by a robust cascade of inflammatory and immune events. In the early stages of infection, COVID-19 patients present progressive lymphocytopenia; however, patients were reported to eventually develop elevated white blood cell and neutrophil counts [2, 5, 127] . In the hyperinflammatory phase, driven by the host immune response, inflammatory markers become elevated and secondary organ damage may occur in what is deemed the cytokine storm. Systemic cytokine elevation is known to be cardiotoxic with the potential to induce profound myocardial injury, as reported in patients treated with chimeric antigen receptor T-cells who develop cytokine release syndrome [76, 128, 129] . Furthermore, cytokine storms may directly mediate ventricular electrical remodeling and significant QT interval prolongation, predisposing for ventricular arrhythmias [130] . Additionally, proinflammatory cytokines are known to promote coagulation and thrombosis by enhancing expression of tissue factor on endothelial cells, activating coagulation factors and inhibiting fibrinolysis, as is observed in severe cases of sepsis [131] .

While the rate of SARS-CoV-2 infection seems to be similar between males and females [15] , the ability to mount an immune response to protect against COVID-19 may contribute to sex differences seen in COVID-19 mortality and cardiac injury. Through a combination of sex biasing factors, females have a greater ability to detect virial infection and generally experience a more robust response to viral infection which could contribute to their protection against COVID-19 when compared to males [132] [133] [134] [135] . Both sex hormones and sex chromosomes influence sex differences in immunity [134, 136] . Sex hormones have been shown to bind to receptors on immune cell surfaces to alter their gene expression and activity [134] . Additionally, the X chromosome encodes a high density of immune-related genes and microRNAs which, despite inactivation of the second X chromosome in females, remain overly expressed in females compared to males, contributing to the heightened immune response in females [136] [137] [138] .

The male-specific Y chromosome, which encodes substantially less genes than its X chromosome counterpart, has also been found to influence immune function as Y chromosome genes are expressed in various immune cell types and have been shown to alter immune function [139, 140] .

Notably, similar sex differences were also observed in the previous coronaviruses SARS and Middle East respiratory syndrome (MERS). In both SARS and MERS outbreaks, males had higher mortality rates than females [15, 141, 142] . Mouse studies investigating SARS, which also infects the airways and lungs through the ACE2 receptor, revealed that infected male and female mice had a unique immune signature compared to males, and estrogen protected against SARS severity partially through mediating this immune response [141] . While the data is still sparse, reports show a sex-specific immune signature may be present in SARS-CoV-2 infection as well. One study found male COVID-19 patients exhibit elevated circulating white blood cells and neutrophils when compared to female patients [15] . Another study revealed male COVID-19 patients exhibit a lower lymphocyte count and elevated levels of IL-10, TNF-α, and CRP compared to females [143] . It remains to be elucidated to which extent the sex differences observed in systemic inflammation in COVID-19 patients translate to differences in inflammation-induced cardiac injury, arrhythmia and microvascular dysfunction and thrombosis.

Arrhythmias in COVID-19 patients may result from biological factors in the pathophysiology of COVID-19 or may be induced by drugs used for treating COVID-19 [144] . While the clinical efficacy of these drugs is still relatively unknown, the antimalarial drugs chloroquine and hydroxychloroquine were shown to have antiviral properties against SARS-CoV-2 in vitro by increasing endosomal pH and interfering with ACE2 glycosylation [145, 146] . Administration of chloroquine and hydroxychloroquine with or without adjunctive azithromycin has been reported to significantly prolong the QT interval in COVID-19 patients [147] [148] [149] [150] [151] . The risk of developing torsade des pointes ventricular arrhythmia and arrhythmic death in COVID-19 patients treated with hydroxychloroquine/chloroquine/azithromycin however does not seem to increase [147] [148] [149] [150] [151] [152] .

Interestingly, an in silico modeling study using mathematical models of ion currents from human ventricular cardiomyocytes and clinically therapeutic drug doses has shown that females with preexisting cardiovascular disease may especially be susceptible to antimalarial drug-induced QT prolongation compared to males with cardiovascular disease or healthy individuals of either sex [153] . Indeed, sex differences in cardiovascular drug responses have been reported and female sex is a known risk factor for drug-induced QT prolongation and torsade des pointes which may be caused by female sex hormones affecting cardiomyocyte ion currents [90, 154] . However, thus far no sex differences have been reported inthe prevalence of QT interval prolongation in COVID-19 patients treated with hydroxychloroquine/chloroquine with or without azithromycin [147, 148, 150] .

Preexisting CVD and cardiovascular injury seem to be a prominent feature of COVID-19 severity and outcome. Research in the COVID-19 field is rapidly evolving; however, the thus-far observed sex disparities already emphasize the need to understand the pathophysiological role of sex hormones and chromosomes in COVID-19 disease progression and COVID-19-related cardiovascular injury. Clinically, studies show that males with preexisting CVD are particularly prone to more severe COVID-19 disease and COVID-19-related cardiovascular injury. As such, sex hormone and chromosome COVID-19 interactions will be a promising field of study to elucidate novel protective mechanisms and therapies for the treatment of COVID-19. Additionally, sex differences in ACE2 expression, inflammation and drug absorption, metabolism and tolerance make it imperative to study sex-specific disparities within COVID-J o u r n a l P r e -p r o o f 19 treatment efficacy. [155, 156] Considering that sex differences in cardiovascular drug responses have been reported, sex differences will be of special interest for treating COVID-19-related cardiovascular injury [154, 157, 158] . Lastly, cardiac abnormalities including myocarditis, fibrosis, edema and left and right ventricular dysfunction have been reported in recovered COVID-19 patients [159] [160] [161] . Although as of yet no sex differences were found in recovered COVID-19 patients, it has been reported previously that males and females exhibit different functional outcome and long-term mortality after myocarditis, cardiac arrest and thrombotic events [109, 159, 162, 163] . Longitudinal follow-up studies will therefore be imperative to gain more insight into the long-term cardiovascular effects and recovery in male and female COVID-19 patients.

None. Preexisting CVD is modulated by sex chromosomes and hormones, ACE2 expression, drug interactions, obesity and smoking, which may predispose males and females differently to COVID-19 severity. CVD, obesity and smoking are risk factors with a higher burden in male vs. female COVID-19 patients (shown with red icons in males). COVID-19 pathogenic mechanisms also contribute to cardiovascular injury. Males exhibit higher burden of cardiac injury than females, while no sex disparities in arrhythmia and microvascular injury and thrombosis have been reported thus far. COVID-19-induced cardiovascular injury is thought to be modulated by sex hormones, ACE2 expression and systemic inflammation, with the latter being more pronounced in males. Altogether, these factors may explain why male COVID-19 patients seem to be at higher risk for severe disease progression and cardiovascular injury compared to females. Red icons reflect sex differences in factors observed in COVID-19 patients, gray icons reflect factors wherein no sex difference has been found in COVID-19 patients or is yet unknown.

J o u r n a l P r e -p r o o f Figure 1 

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States

Coagulopathy in COVID-19

Epidemic of Cardiovascular Disease in China

Status of Hypertension in China: Results From the China Hypertension Survey

The impact of 2019 novel coronavirus on heart injury: A systemic review and Meta-analysis

Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019

Impact of sex and gender on COVID-19 outcomes in Europe

Gender Differences in Patients With COVID-19: Focus on Severity and Mortality

Androgen Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men

Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis

Sex differences in primary hypertension

Gender differences in ischemic heart disease

Sex Differences in Ischemic Heart Disease

Sex differences in heart failure

Chugh Sumeet S. Sex Differences in Cardiac Arrhythmias

Sex differences in thrombosis in mice are mediated by sex-specific growth hormone secretion patterns

The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy

Executive Summary: Heart Disease and Stroke Statistics&#x2014

Sex Hormones and Sex Chromosomes Cause Sex Differences in the Development of Cardiovascular Diseases. Arteriosclerosis, Thrombosis, and Vascular Biology

Sex Chromosome Effects on Male-Female Differences in Mammals

The importance of having two X chromosomes

XX sex chromosome complement promotes atherosclerosis in mice

The number of X chromosomes influences protection from cardiac ischaemia/reperfusion injury in mice: one X is better than two

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism

Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure

Angiotensin-Converting Enzyme 2 Suppresses Pathological Hypertrophy, Myocardial Fibrosis, and Cardiac Dysfunction

Angiotensin-converting enzyme 2 is an essential regulator of heart function

Myocyte Specific Upregulation of ACE2 in Cardiovascular Disease: Implications for SARS-CoV-2 mediated myocarditis

-7)-Forming Activity in Failing Human Heart Ventricles

Pathological Ace2-to-Ace enzyme switch in the stressed heart is transcriptionally controlled by the endothelial Brg1-FoxM1 complex

Myocardial infarction increases ACE2 expression in rat and humans

Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts

Single-cell RNA analysis on ACE2 expression provides insights into SARS-CoV-2 potential entry into the bloodstream and heart injury

A Human Homolog of Angiotensin-converting Enzyme n

Landscape of X chromosome inactivation across human tissues

An Introduction to Epigenetics in Cardiovascular Development, Disease, and Sexualization

Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17beta-oestradiol regulation of renal pathology in renal wrap hypertension in rats

Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice

Sex differences in circulating and renal angiotensins of hypertensive mRen(

Sex Hormones Promote Opposite Effects on ACE and ACE2 Activity, Hypertrophy and Cardiac Contractility in Spontaneously Hypertensive Rats

Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17β-oestradiol-dependent and sex chromosome-independent

Gender differences in the effects of angiotensin receptor blockers on cardiovascular disease

Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure -A population study

Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study

Sex-Based Differences in Drug Activity

Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2

Enalapril Attenuates Downregulation of Angiotensin-Converting Enzyme 2 in the Late Phase of Ventricular Dysfunction in Myocardial Infarcted Rat

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19

Prevalence of obesity among adult inpatients with COVID-19 in France

Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality

Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen

Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit

Obesity and COVID-19: an Italian snapshot

Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study

Sex differences in obesity, lipid metabolism, and inflammation-A role for the sex chromosomes?

Social and Environmental Factors Influencing Obesity

The renin-angiotensin-aldosterone system as a link between obesity and coronavirus disease 2019 severity

Sex difference and smoking predisposition in patients with COVID-19

The 2015 China Adult Tobacco Survey: exposure to second-hand smoke among adults aged 15 and above and their support to policy on banning

Smoking in Italy in 2015-2016: prevalence, trends, roll-your-own cigarettes, and attitudes towards incoming regulations

Current Cigarette Smoking Among Adults -United States

Prevention (US) C for DC and, Promotion (US) NC for CDP and H, Health (US) O on S and. Cardiovascular Diseases

Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov | bioRxiv n

COVID-19 and the Heart

COVID-19-associated coagulopathy: An exploration of mechanisms

Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome

Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis

Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: A meta-regression and Decision tree analysis

Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan

Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies

Cardiac injury, arrhythmia, and sudden death in a COVID-19 patient

Sudden cardiac death in COVID-19 patients, a report of three cases

Association Between Atrial Fibrillation and Sudden Cardiac Death

Clinical characteristics of COVID-19 patients with complication of cardiac arrhythmia

Cardiac and arrhythmic complications in patients with COVID-19

COVID-19 and cardiac arrhythmias

Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study

Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society

Coagulation abnormalities and thrombosis in patients with COVID-19

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Hyperacute multi-organ thromboembolic storm in COVID-19: a case report

Acute pulmonary embolism in COVID-19 related hypercoagulability

Incidence of venous thromboembolism in hospitalized patients with COVID-19

D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study 2020

Elevated D-Dimer Levels are Associated with Increased Risk of Mortality in COVID-19: A Systematic Review and Meta-Analysis. Cardiovascular Medicine

Clotting Factors in COVID-19: Epidemiological Association and Prognostic Values in Different Clinical Presentations in an Italian Cohort

Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice

Pathological study of impact of SARS coronavirus on heart and its conduction system in SARS patients

Myocardial localization of coronavirus in COVID-19 cardiogenic shock

Detection of viral SARS-CoV-2 genomes and histopathological changes in endomyocardial biopsies

Evidence of SARS-CoV-2 mRNA in endomyocardial biopsies of patients with clinically suspected myocarditis tested negative for COVID-19 in nasopharyngeal swab

The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2

Human iPSC-Derived Cardiomyocytes are Susceptible to SARS-CoV-2 Infection

Sex and Gender Differences in Myocarditis and Dilated Cardiomyopathy

Sex and Gender Differences in Zika Myocarditis

The role of sex differences in autophagy in the heart during coxsackievirus B3 induced myocarditis

COVID-19: the vasculature unleashed

Endothelial cell infection and endotheliitis in COVID-19

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Sex differences in endothelial function important to vascular health and overall cardiovascular disease risk across the lifespan

Covid-19 accelerates endothelial dysfunction and nitric oxide deficiency

Intrinsic sex-specific differences in microvascular endothelial cell phosphodiesterases

SARS coronavirus entry into host cells through a novel clathrin-and caveolae-independent endocytic pathway

SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS

Angiotensin-Converting Enzyme 2 Activation Improves Endothelial Function

Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis

ACE2 activation promotes antithrombotic activity

Detection of soluble angiotensinconverting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system

Age and sex differences in soluble ACE2 may give insights for COVID-19

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Cytokine release syndrome

Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)

Cardiac Arrest Risk During Acute Infections: Systemic Inflammation Directly Prolongs QTc Interval via Cytokinemediated Effects on Potassium Channel Expression

Cytokines as Regulators of Coagulation

Sex Drives Dimorphic Immune Responses to Viral Infections

SeXX Matters in Infectious Disease Pathogenesis

The Xs and Y of immune responses to viral vaccines

TLR7 ligands induce higher IFNalpha production in females

Sex differences in immune responses to infectious diseases

The X-chromosome has a different pattern of gene expression in women compared with men with ischemic stroke

Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection

SeXY chromosomes and the immune system: reflections after a comparative study

Cutting edge: the Y chromosome controls the age-dependent experimental allergic encephalomyelitis sexual

Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection

Sex matters -a preliminary analysis of Middle East respiratory syndrome in the Republic of Korea

Gendered effects on inflammation reaction and outcome of COVID-19 patients in Wuhan

Capecchi Pier Leopoldo. COVID-19, Arrhythmic Risk, and Inflammation

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Remdesivir is a directacting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin

Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection

Chloroquine-induced QTc prolongation in COVID-19 patients

Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease

The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

Investigational treatments for COVID-19 may increase ventricular arrhythmia risk through drug interactions

Sex, drugs, and trial design: sex influences the heart and drug responses

Ongoing Clinical Trials for the Management of the COVID-19 Pandemic

Clinical trials for COVID-19 should include sex as a variable

PDE5 inhibitor efficacy is estrogen dependent in female heart disease

Gender differences in the effects of cardiovascular drugs

Cardiac involvement in recovered COVID-19 patients identified by magnetic resonance imaging

Myocarditis detected after COVID-19 recovery

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)

Sex differences in the quality-of-life and functional outcome of cardiac arrest survivors

Sex Differences in Stroke Recovery and Stroke-Specific Quality of Life